https://www.selleckchem.com/products/ml210.html
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited systemic treatment options. RX-5902 is a novel anti-cancer agent that inhibits phosphorylated-p68 and thus attenuates nuclear β-catenin signaling. The purpose of this study was to evaluate the ability of β-catenin signaling blockade to enhance the efficacy of anti-CTLA-4 and anti-PD-1 immune checkpoint blockade in immunocompetent, preclinical models of TNBC. Treatment with RX-5902, anti-PD-1, anti-CTLA-4 or the combination was investigated in BALB/c m
Curtir
Comentario
Compartilhar
